Eli Lilly has publicly endorsed former President Donald Trump’s objective to align international drug prices, aiming to address concerns about foreign countries relying on the U.S. to pay higher costs for medicines. The U.S. pharmaceutical industry is advocating for a rebalancing of drug pricing to better reflect the innovation and value contributed by drugmakers. Concurrently, the Swiss government held meetings with senior executives from major pharmaceutical companies Roche and Novartis to discuss the industry's challenges amid uncertainties caused by U.S. tariffs. These discussions highlight the importance of collaboration between governments and the pharmaceutical sector to navigate the evolving trade and pricing landscape.